The double-upgrade from a top-tier firm is a strong bullish signal, but the downward EPS revision trend and insider sales warrant caution. Traders should watch for confirmation from earnings or further analyst upgrades before committing.
Price Chart
Executive Summary
UBS double-upgraded Medtronic plc (MDT) from Neutral to Buy on July 28, 2026, raising its price target to $100 from $85, implying 18.7% upside from the current $84.22. The firm has a 67% accuracy rate on 6 MDT calls with a 4.1% average return, placing it in the top tier among covering analysts. Consensus is mixed: 22 of 37 analysts rate MDT Buy or Strong Buy (59%), 14 Hold (38%), and 1 Sell (3%), with a mean target of $97.84 and a high of $121. UBS's new $100 target is slightly above the median of $100 and above the mean. The upgrade is contrarian relative to the 30-day EPS revision trend, which shows 26 downward revisions for the current fiscal year and 22 for next year. Insider selling of ~$595K in June-July 2026 by two officers provides a mild bearish contra-signal, but the double-upgrade from a top-tier firm with a 67% accuracy rate carries significant weight. The bottom line: UBS's bold double-upgrade signals a fundamental inflection, but traders should weigh the downward EPS momentum and insider sales against the bullish call.
Impact Score
Consensus & Targets
Consensus is mixed: 10 Strong Buy, 12 Buy (59% bullish), 14 Hold (38%), 1 Sell (3%), 0 Strong Sell, based on 37 analysts. The majority leans bullish, but the 38% hold rating suggests lingering caution.
Current price: $84.22. Mean target: $97.84 (16.2% upside). Median: $100 (18.7% upside). High: $121 (43.7% upside). Low: $78 (7.4% downside). UBS's $100 target is at the median and above the mean, aligning with the bullish consensus.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-28 | UBS | upgrade | Buy | $100.00 |
| 2026-07-10 | TD Cowen | maintain | Buy | $100.00 |
| 2026-07-06 | Evercore ISI Group | maintain | Outperform | $105.00 |
| 2026-06-17 | Needham | reiterate | Buy | — |
| 2026-06-05 | Goldman Sachs | maintain | Neutral | $83.00 |
| 2026-06-05 | Bernstein | maintain | Outperform | $97.00 |
| 2026-06-04 | UBS | maintain | Neutral | $85.00 |
| 2026-06-04 | TD Cowen | reiterate | Buy | $119.00 |
| 2026-06-04 | RBC Capital | reiterate | Outperform | $118.00 |
| 2026-06-04 | Wells Fargo | maintain | Overweight | $102.00 |
30-day analyst activity: 1 upgrade (UBS), 0 downgrades. EPS revisions are bearish: 26 downward revisions for the current fiscal year and 22 for next year in the last 30 days, with no upward revisions. The upgrade is a contrarian signal against the downward revision trend.
Firm Track Record — UBS
UBS accuracy: 55% on 5074 calls | avg return: 4.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 14 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Mizuho | 100% | 2/2 | 11.1% | top tier |
| Bernstein | 100% | 2/2 | 6.4% | top tier |
| Needham | 75% | 9/12 | 4.1% | top tier |
| Baird | 71% | 5/7 | 4.8% | top tier |
| Citigroup | 67% | 4/6 | 3.5% | top tier |
| UBS | 67% | 4/6 | 4.1% | top tier |
| Wells Fargo | 60% | 3/5 | 3.3% | above average |
| Truist Securities | 60% | 6/10 | 4.8% | above average |
| RBC Capital | 56% | 5/9 | 3% | above average |
| Goldman Sachs | 50% | 1/2 | 4.4% | below average |
UBS has a 67% accuracy rate on 6 MDT calls with a 4.1% average return, ranking as top tier. Among covering firms, Mizuho and Bernstein lead with 100% accuracy on 2 calls each, while Barclays and Stifel trail at 33% on 3 calls each.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $1.39 | $1.37 — $1.39 | $9.5B | ↑11 ↓0 |
| 0y | $5.95 | $5.88 — $6.02 | $38.8B | ↑0 ↓0 |
| +1y | $6.40 | $6.20 — $6.65 | $40.2B | ↑1 ↓0 |
| +1q | $1.35 | $1.32 — $1.41 | $9.5B | ↑0 ↓0 |
Cross-Platform Signals
Insider trades show two sales: Walter Matthew R. sold $258K on July 8, 2026, and Kiil Harry Skip sold ~$337K on June 8, 2026. No congressional trades or institutional changes are reported. The insider selling is a mild bearish contra-signal to the bullish upgrade, but sales alone are weak predictors per academic literature.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | Press Release | $92.60 $89.30 | ▼ −3.56% | ▼ −6.13% | $86.38 (−6.72%) |
Sep 15, 2026 16d ago | 425 | $92.60 $89.30 | ▼ −3.56% | ▼ −6.13% | $86.38 (−6.72%) |
Sep 14, 2026 17d ago | 425 | $93.75 $90.77 | ▼ −3.18% | ▼ −5.29% | $86.38 (−7.86%) |
Sep 14, 2026 18d ago | 425 | $93.80 $91.75 | ▼ −2.19% | ▼ −2.29% | $86.38 (−7.91%) |
Sep 14, 2026 18d ago | 425 | $93.80 $91.75 | ▼ −2.19% | ▼ −2.29% | $86.38 (−7.91%) |
Sep 1, 2026 4w ago | Press Release | $92.03 $91.89 | ▼ −0.15% | ▼ −0.23% | $86.38 (−6.14%) |
Sep 1, 2026 4w ago | 8-K | $92.04 $91.89 | ▼ −0.16% | ▼ −0.24% | $86.38 (−6.15%) |
Sep 1, 2026 4w ago | Press Release | $92.04 $91.89 | ▼ −0.16% | ▼ −0.24% | $86.38 (−6.15%) |
Aug 31, 2026 4w ago | Court Ruling | $90.65 $92.39 | ▲ +1.92% | ▲ +2.06% | $86.38 (−4.71%) |
Aug 20, 2026 6w ago | Press Release | $93.35 $91.15 | ▼ −2.36% | ▼ −2.83% | $86.38 (−7.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access